MBX Biosciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 63

Employees

  • Stock Symbol
  • MBX

Stock Symbol

  • Share Price
  • $49.55
  • (As of Friday Closing)

MBX Biosciences General Information

Description

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Contact Information

Website
www.mbxbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11711 North Meridian Street
  • Suite 300
  • Carmel, IN 46032
  • United States
+1 (317)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 11711 North Meridian Street
  • Suite 300
  • Carmel, IN 46032
  • United States
+1 (317)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MBX Biosciences Stock Performance

As of 20-Nov-2026, MBX Biosciences’s stock price is $49.55. Its current market cap is $2.46B with 49.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$49.55 $53.41 $26.00 - $72.64 $2.46B 49.7M 532K -$3.07

MBX Biosciences Financials Summary

As of 30-Sep-2026, MBX Biosciences has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,407,905 1,025,169 339,030
Revenue 0 0 0 0
EBITDA (159,991) (97,807) (67,950) (35,154)
Net Income (145,095) (86,971) (61,922) (32,563)
Total Assets 500,618 385,144 268,535 84,180
Total Debt 3,291 596 171 324
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MBX Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MBX Biosciences‘s full profile, request access.

Request a free trial

MBX Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore MBX Biosciences‘s full profile, request access.

Request a free trial

MBX Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel prec
Drug Discovery
Carmel, IN
63 As of 2025

Abingdon, United Kingdom
 

Basking Ridge, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MBX Biosciences Competitors (59)

One of MBX Biosciences’s 59 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Lisata Therapeutics Corporation Basking Ridge, NJ
Spruce Biosciences Formerly VC-backed South San Francisco, CA
Capricor Therapeutics Formerly VC-backed San Diego, CA
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 59 competitors. Get the full list »

MBX Biosciences Patents

MBX Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024358829-A1 Pharmaceutical compositions and uses thereof Pending 13-Oct-2023
EP-4791425-A1 Pharmaceutical compositions and uses thereof Pending 13-Oct-2023
WO-2025081012-A1 Pharmaceutical compositions and uses thereof Inactive 13-Oct-2023 A61P5/18

MBX Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MBX Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view MBX Biosciences’s complete esg history, request access »

MBX Biosciences FAQs

  • When was MBX Biosciences founded?

    MBX Biosciences was founded in 2018.

  • Where is MBX Biosciences headquartered?

    MBX Biosciences is headquartered in Carmel, IN.

  • What is the size of MBX Biosciences?

    MBX Biosciences has 63 total employees.

  • What industry is MBX Biosciences in?

    MBX Biosciences’s primary industry is Drug Discovery.

  • Is MBX Biosciences a private or public company?

    MBX Biosciences is a Public company.

  • What is MBX Biosciences’s stock symbol?

    The ticker symbol for MBX Biosciences is MBX.

  • What is the current stock price of MBX Biosciences?

    As of 20-Nov-2026 the stock price of MBX Biosciences is $49.55.

  • What is the current market cap of MBX Biosciences?

    The current market capitalization of MBX Biosciences is $2.46B.

  • Who are MBX Biosciences’s competitors?

    Adaptimmune Therapeutics, Lisata Therapeutics, Spruce Biosciences, Capricor Therapeutics, and Alzheon are some of the 59 competitors of MBX Biosciences.

  • What is MBX Biosciences’s annual earnings per share (EPS)?

    MBX Biosciences’s EPS for 12 months was -$3.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process